The ineligible patient: how to treat patients not included in clinical studies.
about
Feasibility, efficacy and safety of tyrosine kinase inhibitor treatment in hemodialyzed patients with renal cell cancer: 10 years of experience.Pazopanib in Patients with Clear-Cell Renal Cell Carcinoma: Seeking the Right Patient.The relationship between eligibility criteria and adverse events in randomized controlled trials of hematologic malignancies.Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma patients.Efficacy and safety of everolimus treatment in a hemodialysis patient with metastatic atypical bronchial carcinoid: case report and literature review.
P2860
The ineligible patient: how to treat patients not included in clinical studies.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The ineligible patient: how to treat patients not included in clinical studies.
@en
type
label
The ineligible patient: how to treat patients not included in clinical studies.
@en
prefLabel
The ineligible patient: how to treat patients not included in clinical studies.
@en
P2860
P1476
The ineligible patient: how to treat patients not included in clinical studies.
@en
P2093
Brian I Rini
Frances J Mao
P2860
P2888
P356
10.1007/S00345-013-1042-2
P577
2013-02-24T00:00:00Z
P6179
1037811323